Active Small Cell Lung Cancer Clinical Trials

Data from ClinicalTrials.gov · Privacy-First Design · No Account Required · No Health Data Stored

Why Consider a Small Cell Lung Cancer (SCLC) Clinical Trial?

• Find Trials That Fit — Browse recruiting Small Cell Lung Cancer (SCLC) trials pulled directly from ClinicalTrials.gov — updated continuously so you always see real, active studies.
• No Medical Jargon — Eligibility criteria are rewritten into plain yes-or-no questions. It's always okay to answer "not sure" — your doctor can help fill in the rest.
• See How Well You Match — Get a clear picture of how closely a trial fits your situation, so you know which ones are worth bringing to your oncologist.
• Ready for Your Appointment — Generate a printable or emailable summary for your next visit. A caregiver can send it to your doctor ahead of time.

How It Works

1. Share a Few Details — Enter your Small Cell Lung Cancer (SCLC) type, stage, and location. No personal health information is required or stored.
2. Answer Yes-or-No Questions — We rewrite complex eligibility criteria into plain language. "Not sure" is always a valid answer.
3. Bring Results to Your Doctor — Get a printable summary with the NCT ID, match assessment, and questions to ask your oncologist.

Free · No account · Nothing you enter is stored

Small Cell Lung Cancer (SCLC) Clinical Trial FAQ

Are there clinical trials for extensive-stage SCLC after prior chemotherapy?

Yes. After platinum-based chemotherapy, several trials are testing lurbinectedin (already FDA-approved as second-line monotherapy), novel DLL3-targeting antibody-drug conjugates (rovalpituzumab tesirine, tarlatamab), bispecific T-cell engagers, and immune checkpoint combinations. SCLC tends to respond to initial therapy but relapse quickly, making these trials important for patients with relapsed disease.

What is DLL3, and why does it matter for SCLC trials?

DLL3 (delta-like ligand 3) is a protein highly expressed on the surface of SCLC cells but not on most normal tissues, making it an attractive target. Tarlatamab, a DLL3-targeting bispecific T-cell engager, received FDA breakthrough designation and is being tested in multiple SCLC trials. Other DLL3-targeted agents (ADCs, CAR-T) are also in early-phase trials.

Does the stage of SCLC (limited vs. extensive) affect which trials I qualify for?

Yes. Limited-stage SCLC (confined to one side of the chest and lymph nodes) is usually treated with concurrent chemoradiation, and trials in this setting often test new radiation schedules or adding immunotherapy to chemoradiation. Extensive-stage SCLC (spread beyond the chest) trials more commonly test systemic therapy combinations. Trialify filters by disease stage so you see the most relevant studies.

Are there SCLC trials for patients who have received brain radiation (PCI)?

Yes. Prophylactic cranial irradiation (PCI) is common in limited-stage SCLC, and prior brain radiation does not automatically exclude you from trials. However, some trials require adequate time since radiation and stable CNS status. Trials specifically focused on brain metastases in SCLC are also available.

How quickly should I look for an SCLC trial given how fast the cancer grows?

SCLC is aggressive and can progress quickly, so it's important to identify trial options early — ideally in parallel with starting standard treatment. Trialify can help you identify matching trials within minutes. Bring the NCT numbers and your match summary to your oncologist so they can help you decide whether a trial or standard therapy is the right first step.

Explore Other Cancer Trial Guides

• Lung Cancer — Lung cancer is the leading cause of cancer-related death worldwide. Recruiting clinical trials are testing new immunotherapies, targeted therapies, and combination regimens for NSCLC and SCLC patients.
• Non-Small Cell Lung Cancer (NSCLC) — Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, representing about 85% of all cases. Trials are testing EGFR, ALK, KRAS, MET, and RET targeted therapies alongside checkpoint immunotherapy for all stages of NSCLC.
• Brain Cancer — Brain cancer trials are testing IDH inhibitors, tumor-treating fields (TTFields), CAR-T therapies, and oncolytic viruses — with studies available for glioblastoma, grade 2/3 glioma, and brain metastases.
• Head and Neck Cancer — Head and neck cancer trials are testing PD-1/PD-L1 checkpoint inhibitors, cetuximab combinations, and organ-preservation strategies for squamous cell carcinoma of the oral cavity, oropharynx, larynx, and hypopharynx.